Kidney Cancer Coverage from Every Angle

Studying NR1B2 as Tumor Suppressor in Renal Clear Cell Carcinoma

By: Joseph Fanelli
Posted: Thursday, September 5, 2019

According to research findings presented in the Journal of Experimental & Clinical Cancer Research, expression of the fusion gene NR1B2 was downregulatged in patients diagnosed with renal clear cell carcinoma and, the authors noted, it may prove to be a tumor suppressor. Guangchun Wang, MD, of the School of Medicine in Tongji University, Shanghai, China, and colleagues determined that NR1B2 may restrict epithelial-mesenchymal transition through the LATS1/2-YAP signaling pathway.

According to the authors, the discovery “not only sheds new light on [renal clear cell carcinoma] progression and metastasis, but also provides a potential target for cancer prevention and treatment.”

In this trial, the investigators analyzed tumors from patients with renal clear cell carcinoma with detailed NR1B2 expression data available through The Cancer Genome Atlas (TCGA) database. The samples were examined by real-time polymerase chain reaction, Western blot, and tissue microarray. The cancer cells were analyzed by migration and invasion assay and then injected into nude mice to determine tumor growth and metastasis.

The authors found that the expression of NR1B2 in these tumors was “significantly downregulated” in the TCGA database as well as in clinical samples. Additionally, NR1B2 expression was found to have a negative correlation with tumor stage and a positive correlation with disease-free and overall survival rates, according to the researchers. The investigators found that this level of expression may be used as an independent factor in predicting the prognosis of patients with renal clear cell carcinoma.

The overexpression of NR1B2 significantly inhibited renal clear cell carcinoma cell invasion and metastasis in both in vitro and in vivo cases, whereas knockdown NR1B2 significantly promoted those same functions.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.